11:02 AM EDT, 04/09/2024 (MT Newswires) -- Syros Pharmaceuticals ( SYRS ) said Tuesday it has received the fast track designation from the US Food and Drug Administration for tamibarotene plus azacitidine and venetoclax to treat acute myeloid leukemia with RARA overexpression in people over 75 years or with comorbidities that preclude the use of intensive induction chemotherapy.

Tamibarotene is being assessed in combination with venetoclax and azacitidine for the treatment of newly diagnosed acute myeloid leukemia with RARA gene overexpression, the company said.

The company's shares were rising past 13% in recent trading.

Price: 5.06, Change: +0.56, Percent Change: +12.44